About Michael Morton

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.

ApconiX Welcomes Bethany Russell

Bethany joins ApconiX as a placement student for part of September.  A second-year student, Bethany is studying Biomedical Sciences at Sheffield University.  Her degree is a four-year sandwich course, with a third-year placement in industry. Bethany was unsure if a career in a laboratory was for her and wanted to be clearer before making her [...]

By |2018-09-25T18:03:38+00:00October 4th, 2018|Ion Channels, Careers|Comments Off on ApconiX Welcomes Bethany Russell

ApconiX is supporting PhysioStim at SPS

ApconiX and PhysioStim will be celebrating their first year of The European Centre of Excellence for preclinical cardiovascular electrophysiology at the Safety Pharmacology Society Annual Meeting in Washington this September.  ApconiX will be supporting PhysioStim as they exhibit at the Marriott Wardman Park Hotel on Stand 412 from the 30th of September to the 3rd [...]

By |2018-09-25T18:23:43+00:00September 26th, 2018|Ion Channels, Events|Comments Off on ApconiX is supporting PhysioStim at SPS

Michael Morton Presents at EUROTOX 2018

Dr Michael Morton will be speaking at EUROTOX this September in Belgium.  On Tuesday September 4th at 16:30 in Hall 100 Mike will address ‘Cardiac safety: current state of the art’ chaired by Dr Mark Holbrook of VAST Pharma solutions and Ester Lovsin-Barle from Lonza.  Mike will present ‘Ion channel profiling of stem cell-derived cardiomyocytes: [...]

By |2018-08-23T12:05:35+00:00August 29th, 2018|Ion Channels, Events|Comments Off on Michael Morton Presents at EUROTOX 2018

ApconiX Welcomes George Buchanan

George joins ApconiX as a placement student for the month of August.  George graduated from the University of Newcastle last year after studying Biology.  He decided to take a year out before beginning a master’s degree in stem cell technology and regenerative medicine at the University of Nottingham in September. George was keen to gain [...]

By |2018-07-31T13:02:03+00:00July 31st, 2018|Ion Channels, Careers|Comments Off on ApconiX Welcomes George Buchanan

ApconiX Welcomes Katie Cox

Katie joins ApconiX as a placement student for the month of July.  Katie, a third-year student from Sheffield University studying Biomedical Sciences hopes to carry on with her studies and complete a master’s degree at Sheffield after graduation. Eager to gain experience of a real-world laboratory, Katie took her tutor’s advice and applied.  Dr Stephen [...]

By |2018-07-31T10:46:01+00:00July 5th, 2018|Ion Channels, Careers|Comments Off on ApconiX Welcomes Katie Cox

ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

Why is Time Critical to hERG Screening Data? ApconiX has worked hard to optimise our processes and is now returning over 80% of hERG screening data back to clients within one week of compound receipt.  This allows critical decisions to be made in medicinal chemistry on a full dataset of compound properties, avoiding mistakes and [...]

By |2018-07-19T16:25:00+00:00March 5th, 2018|Ion Channels|Comments Off on ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

ApconiX Welcomes Dr Karen Jones to The Team.

ApconiX is delighted to welcome Dr Karen Jones who joins us from AstraZeneca.  Karen, a talented electrophysiologist, will work with Dr Michael Morton to ensure the laboratory continues to provide an outstanding service as the demand for ion channel and cardiovascular safety screening increases. Karen graduated from the University of Liverpool with a degree in [...]

By |2018-07-11T14:36:29+00:00December 2nd, 2017|Ion Channels, Careers|Comments Off on ApconiX Welcomes Dr Karen Jones to The Team.

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

ApconiX Announce Their Alliance with PhysioStim.

The European Centre of Excellence for preclinical cardiovascular electrophysiology. The ApconiX team is pleased to announce their alliance with PhysioStim to create a new Centre of Excellence dedicated to cardiac safety studies. Both companies team up to offer a complete range of services in nonclinical cardiovascular electrophysiology. ApconiX, based at Alderley Park in the U.K. [...]

By |2018-06-20T16:06:07+00:00September 21st, 2017|Ion Channels, Press|Comments Off on ApconiX Announce Their Alliance with PhysioStim.

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure